An Analytical and Numerical Study of Optimal Channel Networks

We analyze the Optimal Channel Network model for river networks using both analytical and numerical approaches. This is a lattice model in which a functional describing the dissipated energy is introduced and minimized in order to find the optimal configurations. The fractal character of river networks is reflected in the power law behaviour of various quantities characterising the morphology of the basin. In the context of a finite size scaling Ansatz, the exponents describing the power law behaviour are calculated exactly and show mean field behaviour, except for two limiting values of a parameter characterizing the dissipated energy, for which the system belongs to different universality classes. Two modified versions of the model, incorporating quenched disorder are considered: the first simulates heterogeneities in the local properties of the soil, the second considers the effects of a non-uniform rainfall. In the region of mean field behaviour, the model is shown to be robust to both kinds of perturbations. In the two limiting cases the random rainfall is still irrelevant, whereas the heterogeneity in the soil properties leads to new universality classes. Results of a numerical analysis of the model are reported that confirm and complement the theoretical analysis of the global minimum. The statistics of the local minima are found to more strongly resemble observational data on real rivers.Comment: 27 pages, ps-file, 11 Postscript figure

Theory for the coalescence of viscous lenses

Drop coalescence occurs through the rapid growth of a liquid bridge that connects the two drops. At early times after contact, the bridge dynamics is typically self-similar, with details depending on the geometry and viscosity of the liquid. In this paper we analyse the coalescence of two-dimensional viscous drops that float on a quiescent deep pool; such drops are called liquid lenses. The analysis is based on the thin-sheet equations, which were recently shown to accurately capture experiments of liquid lens coalescence. It is found that the bridge dynamics follows a self-similar solution at leading order, but, depending on the large-scale boundary conditions on the drop, significant corrections may arise to this solution. This dynamics is studied in detail using numerical simulations and through matched asymptotics. We show that the liquid lens coalescence can involve a global translation of the drops, a feature that is confirmed experimentally

The Intrinsic Absorber in QSO 2359-1241: Keck and HST Observations

We present detailed analyses of the absorption spectrum seen in QSO 2359-1241 (NVSS J235953-124148). Keck HIRES data reveal absorption from twenty transitions arising from: He I, Mg I, Mg II, Ca II, and Fe II. HST data show broad absorption lines (BALs) from Al III 1857, C IV 1549, Si IV 1397, and N V 1240. Absorption from excited Fe II states constrains the temperature of the absorber to 2000K < T < 10,000K and puts a lower limit of 10^5 cm^{-3} on the electron number density. Saturation diagnostics show that the real column densities of He I and Fe II can be determined, allowing to derive meaningful constraints on the ionization equilibrium and abundances in the flow. The ionization parameter is constrained by the iron, helium and magnesium data to -3.0 < log(U) < -2.5 and the observed column densities can be reproduced without assuming departure from solar abundances. From comparison of the He I and Fe II absorption features we infer that the outflow seen in QSO 2359-1241 is not shielded by a hydrogen ionization front and therefore that the existence of low-ionization species in the outflow (e.g., Mg II, Al III, Fe II) does not necessitate the existence of such a front. We find that the velocity width of the absorption systematically increases as a function of ionization and to a lesser extent with abundance. Complementary analyses of the radio and polarization properties of the object are discussed in a companion paper (Brotherton et al. 2000).Comment: 30 pages, 9 figures, in press with the Ap

HV 11423: The Coolest Supergiant in the SMC

We call attention to the fact that one of the brightest red supergiants in the SMC has recently changed its spectral type from K0-1 I (December 2004) to M4 I (December 2005) and back to K0-1 I (September 2006). An archival spectrum from the Very Large Telescope reveals that the star was even cooler (M4.5-M5 I) in December 2001. By contrast, the star was observed to be an M0 I in both October 1978 and October 1979. The M4-5 I spectral types is by far the latest type seen for an SMC supergiant, and its temperature in that state places it well beyond the Hayashi limit into a region of the H-R diagram where the star should not be in hydrostatic equilibrium. The star is variable by nearly 2 mag in V, but essentially constant in K. Our modeling of its spectral energy distribution shows that the visual extinction has varied during this time, but that the star has remained essentially constant in bolometric luminosity. We suggest that the star is currently undergoing a period of intense instability, with its effective temperature changing from 4300 K to 3300 K on the time-scale of months. It has one of the highest 12-micron fluxes of any RSG in the SMC, and we suggest that the variability at V is due primarily to changes in effective temperature, and secondly, due to changes in the local extinction due to creation and dissipation of circumstellar dust. We speculate that the star may be nearing the end of its life.Comment: Accepted by the Astrophysical Journa

A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2.

In a pilot study six patients received 4 days' treatment with interleukin 2 (IL-2) [cumulative dose (CD) 264 +/- 26 x 10(6) IU m-2] and C1 esterase inhibitor (C1-INH) (loading dose 2,000 U, followed by 500-1,000 U twice daily). Toxicity was compared with that in patients given 4 days' treatment with standard (CD 66 +/- 12 x 10(6) IU m-2) or escalating-dose (CD 99 +/- 8 x 10(6) IU m-2) IL-2. IL-2-induced hypotension was equivalent and complement activation was less after IL-2 + C1-INH (C3a = 10.5 +/- 3.2 nmol l-1) than following standard (14.1 +/- 8.4 nmol l-1) or escalating-dose (18.3 +/- 2.9 nmol l-1) IL-2. This study demonstrates that C1-INH administration during IL-2 treatment is safe and warrants further study to evaluate its ability to ameliorate IL-2-induced toxicity

The Effect of wake Turbulence Intensity on Transition in a Compressor Cascade

Direct numerical simulations of separating flow along a section at midspan of a low-pressure V103 compressor cascade with periodically incoming wakes were performed. By varying the strength of the wake, its influence on both boundary layer separation and bypass transition were examined. Due to the presence of small-scale three-dimensional fluctuations in the wakes, the flow along the pressure surface undergoes bypass transition. Only in the weak-wake case, the boundary layer reaches a nearly-separated state between impinging wakes. In all simulations, the flow along the suction surface was found to separate. In the simulation with the strong wakes, separation is intermittently suppressed as the periodically passing wakes managed to trigger turbulent spots upstream of the location of separation. As these turbulent spots convect downstream, they locally suppress separation. © 2014 Springer Science+Business Media Dordrecht

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy

Anti-EGFR targeted therapy is a potent strategy in the treatment of metastatic colorectal cancer (mCRC) but activating mutations in the KRAS gene are associated with poor response to this treatment. Therefore, KRAS mutation analysis is employed in the selection of patients for EGFR-targeted therapy and various studies have shown a high concordance between the mutation status in primary CRC and corresponding metastases. However, although development of therapy related resistance occurs also in the context of novel drugs such as tyrosine kinase-inhibitors the effect of the anti-EGFR treatment on the KRAS/BRAF mutation status itself in recurrent mCRC has not yet been clarified. Therefore, we analyzed 21 mCRCs before/after anti-EGFR therapy and found a pre-/posttherapeutic concordance of the KRAS/BRAF mutation status in 20 of the 21 cases examined. In the one discordant case, further analyses revealed that a tumor mosaicism or multiple primary tumors were present, indicating that anti-EGFR therapy has no influence on KRAS/BRAF mutation status in mCRC. Moreover, as the preselection of patients with a KRASwt genotype for anti-EGFR therapy has become a standard procedure, sample sets such ours might be the basis for future studies addressing the identification of potential anti-EGFR therapy induced genetic alterations apart from KRAS/BRAF mutations